Trademark Search  /  LIRUM

LIRUM

● Live · Pending

U.S. federal trademark · Serial No. 97926852

Mark
LIRUM
Status
Pending
Serial Number
97926852
Filing Date
May 9, 2023
Class(es)
Class 005, Class 042

Owners

Lirum Therapeutics, Inc.
03 · New York, NY
Lirum Therapeutics, Inc.
03 · New York, NY

Goods & Services

Pharmaceutical preparations and substances for human use for the treatment and prevention of diseases and disorders, namely, oncology, neurodegenerative, ophthalmology, autoimmune, debilitating, degenerative, and infectious diseases and disorders; pharmaceuticals for human use, namely, oncology, neurodegenerative, ophthalmology and autoimmune pharmaceuticals; pharmaceuticals for the treatment of debilitating, degenerative, and infectious diseases

Medical and scientific research, namely, conducting clinical trials for others; consulting services for others in the field of design, planning, implementation, and project management of clinical trials; providing medical and scientific research information in the field of pharmaceuticals, biopharmaceuticals, therapeutics, clinical trials, and studies; testing of pharmaceuticals, biopharmaceuticals, therapeutics, and drugs; research and development of pharmaceuticals, biopharmaceuticals, therapeutics, and drugs; consulting in the field of pharmaceutical, biopharmaceutical, and biotech drug development services; clinical and scientific research and development in the field of pharmaceuticals and biopharmaceuticals; providing medical and scientific research information and data relating to pharmaceuticals, biopharmaceuticals, therapeutics, and medical and scientific research and development; research and development of pharmaceuticals and drug candidates

Thinking of using a similar name?
Search 14 million+ trademarks free and see if your brand conflicts with "LIRUM" or anything like it, before you file.
Run a free trademark search →

Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.